Interpace Biosciences, Inc. (IDXG) Social Stream

Featured Post From StockTwits About IDXG

$IDXG HUGE Rev beat almost EBITDA break even NICE

Q2 Revenue of $11.2 Million Surpasses Q1 2021 as Company’s Highest Revenue Quarter
● Company approaching EBITDA breakeven on Higher Clinical Volume, Revenue, Improved Gross Profit and Operating Expense Containment
● Restructuring Exceeding Full-Year Savings Expectations
● On Track to Exceed Full Year 2021 Revenue Growth of 35%
● Q2 Cash Collections in Excess of $11 Million Representing Highest Collection Quarter

https://ir.interpace.com/press-releases/detail/206/interpace-biosciences-announces-second-quarter-2021